Celcuity Inc. (NASDAQ:CELC) is reporting second quarter earnings results on Monday 10th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.18 per share.
For the full year, analysts predict loss of $ 0.72 per share.
Previous Quarter Performance
Celcuity Inc. came out with loss for the first quarter of $ 0.22 per share, from the revenue of . According to street consensus, loss of $ 0.17 was expected per share The bottom line results missed street analysts by $ 0.05 or 29.41 percent, at the same time, top line results analysts by $ 3.33 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of CELC was $ 6.12, representing a 51.86 % increase from the 52 week low of $ 4.03 and a 70.66 % decrease over the 52 week high of $ 20.86.
The company has a market capital of $ 62.88 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CELC” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Celcuity Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.celcuity.com
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The companys CELx diagnostic platform uses a patients living tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer.
